Skip to content

A study exploring the ease with which placebo Suboxone sublingual films can be removed from the mouth after specified times, when administered stacked on top of each other compared to spaced out around the mouth.

An open-label study in Suboxone maintained clients exploring the effect of a stacked versus spaced oral administration of placebo Suboxone sublingual films on the ability to remove all or some of the films from the mouth after specified times.

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000161628
Enrollment
42
Registered
2014-02-10
Start date
2014-02-10
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Participants will be provided with placebo film (equivalent in number to their usual Suboxone film dose denomination) and will be asked to try to remove the film following its administration sublingually. This will be repeated at various time points following administration (ie. 15 seconds, 30 seconds and 1 minute), under 2 different conditions. That is, the adherence of the film in the mouth (and subsequently ability to remove the film(s)) will be explored when multiple films are stacked as well as when spaced.

Interventions

This study will adopt a repeated measures crossover design with two conditions: film stacking and film spacing. The ease with which the film can be removed from the mouth, following dosing, will be examined. Participants will be provided with placebo film (equivalent in number to their usual dose denomination) and will be asked to try to remove the film following its administration. This will be repeated at various time points: 15 seconds, 30 seconds and 1 minute following administration. Hence,

This study will adopt a repeated measures crossover design with two conditions: film stacking and film spacing. The ease with which the film can be removed from the mouth, following dosing, will be examined. Participants will be provided with placebo film (equivalent in number to their usual dose denomination) and will be asked to try to remove the film following its administration. This will be repeated at various time points: 15 seconds, 30 seconds and 1 minute following administration. Hence, each subject will undergo six different dosing conditions (except for the patients on 1 Suboxone Film where stacking cannot occur, with only 3 conditions). Patients will be asked to estimate the proportion of the film removed on each occasion (none, partial, whole). All sessions will be conducted in a random order design, with 6 subjects required for those receiving one Film, and 12 subjects for each number of multiple films being administered (2,3 or 4), for a total of 42 subjects. For the stacking conditions, participants will be instructed to administer the film by stacking (i.e. with more than 1 film, the participants will be asked to make the multiple films overlap). For the spaced (side by side) conditions, participants will be instructed to follow specific placement of the films in their mouth (i.e. maximum of 2 films to be placed side-by-side under the tongue and other films buccally on each cheek). Participants will be required to wait 15 minutes between each testing application and have a drink (30ml) of water immediately prior to administering film on each occasion. Hence each session should take approximately 3 hours per participant.

Sponsors

South Eastern Sydney Local Health District
Lead SponsorGovernment body

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

a) In Suboxone Film treatment (2-32mg/day) for at least 1 month b) Aged 18 years or over c) Confirmed as not pregnant with urine HCG (for female participants) d) Able to give written informed consent

Exclusion criteria

a) Participants who, in the opinion of the investigators, cannot fulfil the requirements of the protocol b) Participants with concomitant severe, untreated medical or psychiatric conditions (as confirmed by treating clinician).

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026